This move is archived. Current quotes and coverage live on the stock page.
Get CRDL alerts:
Cardiol Therapeutics Inc Class A (CRDL.TO) faced a significant setback in its stock performance today, closing down 1.32%.
In the latest trading session, Cardiol's shares dropped to CA$1.49, raising concerns among investors. This decline highlights the volatility often seen in biotech stocks, especially those still in the developmental phase.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$353.97M
52W high
$3.15
52W low
$1.23
1W change
+1.35%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 99.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+99.3% Upside
Current Price
C$3.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
72.5%
Annualized
90-Day Vol
57.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.60
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.19 | C$2.49 – C$4.10 |
| 60 trading days | C$3.39 | C$2.38 – C$4.83 |
| 90 trading days | C$3.60 | C$2.33 – C$5.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious with Cardiol Therapeutics as the stock continues to experience fluctuations, influenced by market sentiment and the company's developmental milestones.
Cardiol Therapeutics Stock Drops 1.32% in One Day
With a market cap of CA$171.76 million, today’s drop reflects broader investor concerns about the company's ongoing clinical trials and market positioning.
Bull case
If Cardiol can successfully advance its clinical trials and achieve positive results, it may attract renewed interest from investors and drive the stock price higher.
Bear case
The recent decline might indicate underlying issues or skepticism about the company's future, especially if upcoming trial results fall short of expectations.
Advertisement
Market Reaction to Cardiol's Performance
Today's decline in Cardiol Therapeutics' stock stems from a mix of market sentiment and the inherent risks of biotech investments. The lack of recent positive news may have made investors hesitant, contributing to the drop in share price.
Future Outlook and Investor Sentiment
As Cardiol Therapeutics progresses with its clinical trials, particularly the Phase III MAVERIC trial, investor sentiment will likely depend on the outcomes of these studies. If the company delivers promising results, it could reverse today’s losses and restore confidence among shareholders.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
